Abstract. The metabolic clearance rate (MCR) and plasma disappearance rate (t1/2) ofhuman pancreatic tumor growth hormone releasing factor ] was determined in normal adult male subjects by single injection and constant infusion techniques. Single injections of 1, 3.3, and 10 ,Lg/kg hpGRF(l-40) were administered intravenously, plasma immunoreactive (IR) GRF levels were measured during the subsequent 180 min, and biexponential curve analysis was performed. Graded, dose-constant infusions of hpGRF(1-40) at rates of 1, 3.3, 10, and 33 ng/kg per min were administered and the MCR was calculated from measurement of steady state plasma IR-GRF levels at each infusion rate. The postinfusion disappearance rate was determined by linear regression analysis of plasma IR-GRF levels during the 120-min period after cessation of the infusion.
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The calculated MCR during the single injection study was 194±17.5 liters/M2 per d and was not significantly different from the calculated value during the constant infusion study (202±16 liters/M2 per d). The disappearance rate during the single injection study was subdivided into two linear phases: an initial equilibration phase (7.6±1.2 min) and a subsequent elimination phase (51.8±5.4 min). The latter was similar to the linear disappearance rate observed (41.3±3.0 min) after cessation of the constant infusion. The chromatographic and bi-Introduction Growth hormone secretion is regulated by both stimulatory and inhibitory factors of hypothalamic origin. The inhibitory factor is represented by somatostatin, a tetradecapeptide, which appears to be similar in all mammalian species from which it has been isolated to date (1) . Growth hormone releasing factor (GRF)1 has recently been isolated and sequenced from ectopic sites of production in two pancreatic islet tumors (human pancreatic GRF [hpGRF]) (2) (3) (4) . In one tumor only a single GRF with a 40-amino acid sequence was isolated (3) (4) (5) , whereas the other tumor contained the identical GRF as the major component along with 44-and 37-amino acid peptides (2) . The structure of human hypothalamic GRF remains to be determined, though preliminary evidence indicates that it is similar in physicochemical and immunologic characteristics to ectopic GRF (6, 7) ; and two immunologically related peptides which coeluted with hpGRF(1-40) and hpGRF have now been isolated and show identical tryptic digest patterns and amino acid composition (8) .
The rapid decrease in serum GH levels after removal of a GRF-secreting tumor suggests a rapid metabolic clearance of GRF (9) . However, administration of hpGRF to normal human subjects resulted in a rise in serum growth hormone levels (10) that persisted, after high doses, for up to 3 h, and frequently exhibited a biphasic pattern (1 1). Since the clearance of growth hormone from circulation is fairly rapid (12) , the persistence of growth hormone secretion for this prolonged duration indicated a continuous effect ofhpGRF(I -40) and implied a slower metabolic clearance of the peptide than has been reported for other hypophysiotropic hormones such as thyrotropinreleasing hormone, gonadotropin-releasing hormone, and somatostatin (13) (14) (15) . The present studies were therefore performed to determine the metabolic clearance rate (MCR) and plasma disappearance time of hpGRF( 1-40) in normal human subjects with both single-injection and constant-infusion techniques.
Methods
Clinical studies SUBJECTS STUDIED. Experiments were performed in 18 healthy adult male subjects whose ages ranged from 22 to 30 yr and who were within 15% of ideal body weight. All subjects gave informed, written consent. Experiments were conducted under identical protocols in the General Clinical Research Centers at the University ofCincinnati and University of Virginia Hospitals to which subjects were admitted the evening before or the morning of study. The subjects consumed no food for 10 h before or during the study. Indwelling butterfly needles were placed in forearm veins and kept patent with heparinized saline for infusion/injection and blood sampling. Blood pressure and pulse were monitored throughout the study at frequent intervals. Subjects were studied in random order in each of the protocols.
HORMONE PREPARATION. All experiments were performed with hpGRF(1-40), which was synthesized (3, 4) and prepared (10) as previously described.
PROTOCOLS. Single injection protocol. After obtaining a basal sample, subjects were given a rapid intravenous injection of hpGRF Bioassay of GRF GRF activity of plasma extracts was measured in a dispersed rat pituitary cell monolayer culture system as previously described (17, 18) , which was modified by using serum-free media supplemented with bovine insulin, 10 ,g/ml, and corticosterone, 10-8 M (Sigma Chemical Co., St. Louis, MO), during the 4 d before testing. Growth hormone release was measured during a 4-h incubation period in quadruplicate cultures. At the end of the incubation, the media was collected and frozen for subsequent radioimmunoassay ofrat growth hormone as previously described (19 program (20) . The data were fitted to the biexponential equation C(t) = -Aec' + Be-', where t = time, C(t) = the plasma concentration of IR-GRF at each time point, and A and a are the parameters for the alpha (distribution) and B and , the parameters for the beta (elimination) phases, respectively. The When plasma from normal subjects was applied to a Seppak, endogenous IR-GRF was not retained. Immunoassay of the lyophilized and reconstituted 80% ACN/TFA effluent resulted in undetectable levels (<124 pg/ml) in nine subjects. Addition of synthetic hpGRF(1-40) (5 ng/ml) to plasma immediately before its application to Sep-pak columns resulted in an 80.1±2.2% recovery (n = 38). There was no significant difference in recovery when Sep-paks were used in a recycled manner for up to 11 applications.
These findings were interpreted to indicate that endogenous GRF immunoreactivity in unextracted plasma was attributable to a yet undefined material(s) distinct from GRF. Consequently, all subsequent measurements of IR-GRF levels were performed on extracted plasma. Values were not corrected for recovery.
The addition of aprotinin to plasma prevented the degradation (<5%) of '251-hpGRF(1-40) for at least 48 h at 40C and 2 h at 370C. In the absence of aprotinin, significant (>10%) degradation was noted after 6 and 1 h, respectively.
Single injection studies. Plasma IR-GRF levels were undetectable in all of the subjects before GRF injection. Levels of IR-GRF at each of the time periods are shown in Fig. 1 . The combined disappearance curve is shown in Fig. 2 , where the data has been transformed as a function of the injected dose.
The disappearance of IR-GRF from plasma could be fitted to between the doses studied, which suggested nonsaturation of the elimination mechanism.
Constant infusion studies. Plasma IR-GRF levels during the constant infusion of hpGRF(1-40) at rates of 1, 3.3, 10, and 33 ng/kg per min are shown in Fig. 3 . Plasma IR-GRF levels appeared to stabilize -60 min after the start of each infusion and the MCR was calculated from plasma values measured after this time. Table II contains the MCR calculations in these subjects. There was no significant difference between the MCR at the different infusion rates. The overall mean MCR was 202±16 liters/m2 per d.
Plasma IR-GRF levels were measured in eight subjects after discontinuation of the 33 ng/kg per min infusion. The plasma levels could be fit to a single exponential curve during the 90-min postinfusion period and the results are shown in Fig. 4 . Analysis of the plasma disappearance curves yielded a half-time of 41.3±3.0 min when analyzed as individual curves (Table III) and 47.7 min when analyzed as a composite curve. The calculated concentration before the cessation of infusion was 8.43±1.15 ng/ml, a value similar to that observed experimentally (8.51±1.92 ng/ml). plasma (27) . Normal plasma, after elution from the cartridge, contained no detectable IR-GRF and therefore no problem was encountered in distinguishing endogenous from exogenous GRF. The MCR of hpGRF( 1-40), as determined by the constant infusion and single injection techniques, varied by <5% and were statistically indistinguishable from one another. The metabolic clearance was independent of dose in each of the studies, indicating that mechanisms for removal of GRF from plasma had not reached saturation. The disappearance curves after the single injection of hpGRF(1-40) differed from those after discontinuation of the constant infusion with the former exhibiting a biexponential curve and the latter a monoexponential curve. This can readily be explained by the fact that the biexponential curve represents the composite of an equilibration phase (a-phase), representing the filling of the extra vascular compartment, and an elimination phase (,3-phase), representing the irreversible removal of IR-GRF from plasma. The monoexponential curve observed after termination of the constant infusion indicates the presence of a predominant $-phase, since the extravascular compartment was filled and equilibrated during the period ofconstant infusion. The similarity of the half-times calculated from the two techniques strongly supports this interpretation.
The clearance of hpGRF( 1-40) from human plasma is considerably slower than that of several other hypothalamic hormones (thyrotropin-releasing hormone, gonadotropin-releasing hormone, somatostatin) whose t1/2 ranges from I to 10 min (13) (14) (15) but is similar to that of corticotropin-releasing factor (28) . This is in part related to the size of hpGRF( 1-40) which is similar to the 41-amino acid corticotropin-releasing factor but much larger than the other peptides which range from 3-to 14-amino acids. However, factors other than size are also important since the plasma disappearance rate of ACTH, a 39-amino acid peptide, is considerably faster. In contrast to hpGRF 1.0 radation, which also contributes to its relatively shorter halflife (29) .
Knowledge of the MCR of a hormone is important in determining its production rate which, with respect to peptide hormones, represents its secretion rate. This has its greatest significance when the hormone is transported from the site of its secretion to its site(s) of action through the same circulation as is used to study its metabolic clearance. For GRF and the other hypothalamic hormones, however, these criteria are not fulfilled since their physiologic circulation is restricted to the hypothalamic-pituitary portal system, only a few millimeters in length. This distance is sufficiently small and the time required to reach the target cells in the pituitary is correspondingly short, so considerations of metabolic clearance are of little biologic importance.
In contrast, these considerations do not apply when ectopic GRF production (30) is considered. Here, the MCR becomes ofgreat importance since GRF must travel through the peripheral circulation to reach the pituitary. The stability of hpGRF(l-40) in plasma and its relatively slow MCR result in higher plasma levels and greater biologic effects at the same secretion rate than would otherwise occur.
If plasma hormone levels are measureable, knowledge of the MCR can provide an indication of the secretion rate (secretion rate = MCR X plasma level) ofthe peptide by the tumor. In one patient with ectopic GRF production (9) we have determined the plasma IR-GRF level to be 3.8 ng/ml (Frohman, L. A., J. L. Thominet, and M. 0. Thorner, manuscript in preparation), which results in a calculated secretion rate of 21 1Ag/ d. The total tumor GRF content based on its weight and IR-GRF concentration (7) was 880 gg, indicating a turnover rate of 2.4%. The absence of information concerning the turnover rate of GRF in the human hypothalamus precludes a reliable estimate of hypothalamic GRF secretion. However, the marked difference in GRF content between the tumor and the human hypothalamus, where preliminary results indicate levels to be in the submicrogram range (7) , implies a considerably lower hypothalamic secretion rate.
Finally, the information provided by the disappearance rate study may provide a partial explanation for the more prolonged GH responses, particularly at 2 and 3 h noted after injection of high doses ( 1-10 ug/kg) of GRF (1 1). Whereas the minimal hpGRF(1-40) concentration in peripheral plasma required for stimulating GH release is unknown, we have recently reported that a constant infusion of 1 ng/kg per min is sufficient to elicit the plasma GH response in normal subjects (31) . In the present study, this dose resulted in a plasma IR-GRF level of 0.35 ng/ ml. Examination of the GRF disappearance curves (Fig. 1) indicates that plasma IR-GRF levels after injection of 3.3 or 10 ,ug/kg doses remained above this level for at least 3 h, and after the 1 ,tg/kg dose, for 2 h, thereby providing a continuous stimulus for GH release.
In conclusion, we have described methodology for measuring plasma IR-GRF levels after exogenous administration and have determined the MCR and plasma disappearance rate of hpGRF( 1-40) after both single injection and constant infusion. The results have been extrapolated to provide estimates ofGRF secretion rates in patients with ectopic GRF production.
